South Korea’s FTC Looking Into Sanofi Aventis and Novartis For Price Inflation – Industry Insiders
This article was originally published in PharmAsia News
Executive Summary
SEOUL - As South Korea's government agencies move to tighten surveillance on illegal and unfair deals in the pharma industry, the Fair Trade Commission is now looking into several companies including Sanofi-Aventis and Novartis to investigate inflated prices on their products which are considerably more expensive in South Korea than in other countries such as the U.S. and UK, according to industry insiders